Will CMS pay for utilization of AI software that’s similar to an established NTAP earner?

In September CMS agreed to reimburse hospitals for using the first AI software to qualify for Medicare’s New Technology Add-on Payment mechanism (NTAP).

The software is Viz.ai’s stroke package called Viz LVO (aka Viz ContaCT), which speeds time to treatment for stroke. Thanks to the qualification, its utilization with CT imaging can generate reimbursement of up to $1,040 per use for the deploying hospital or stroke center.

Now comes a boomlet in vendors looking to piggyback on Viz.ai’s success, according to Niall Brennan, MPP, a member of Viz.ai’s advisory board who is also the head of the Healthcare Cost Institute.

Since the landmark NTAP approval, “more than five companies have claimed the rights to the code, ranging from stroke triage, to radiology prioritization, and even to CAD,” Brennan writes in a sponsored piece published Dec. 16 in Health Imaging.

“The question is,” he continues, “does this code apply to everyone who wants it?”

In exploring the main factors affecting the answer, Brennan cautions hospitals against betting on reimbursement for using similar software from vendors other than Viz.ai.

He also suggests specific questions hospitals should ask such vendors prior to purchasing their products.

“Without official word from CMS,” Brennan writes, “hospitals have to choose whether to take a risk—as the decision lies with individual hospitals’ risk tolerance as to the technology they want to use and submit for NTAP payments.”

Read the piece at Health Imaging.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.